Citations

Showing 10 of 108119 citations.

Impact of access to NCI/NCCN-designated cancer centers (CC) on overall survival (OS) in multiple myeloma (MM) patients (pts).
Advani, Pooja , Ghosh, Radhika , Swaika, Abhisek, Gupta, Deepansh, Foran, James M. , Colón‐Otero, Gerardo , Chanan‐Khan, Asher , Yang, Dongyun , Gupta, Deepansh, Roy, Vivek , Ailawadhi, Sikander

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e17570-e17570

10.1200/jco.2015.33.15_suppl.e17570 Get It

Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes, NRG Oncology/RTOG 9501-0234.
Divi, Vasu , Cooper, Jay S., McHugh, Jonathan B. , Bell, Diana , Suntharalingam, Mohan, Raben, David, Kim, Harold E., Spencer, Sharon A., Laramore, George E. , Trotti, Andy, Foote, Robert L. , Schultz, Christopher J. , Zhang, Qiang , Harris, Jonathan , Harari, Paul M. , Sturgis, Erich M. , Cmelak, Anthony J. , Thorstad, Wade , Le, Quynh‐Thu , Holsinger, F. Christopher

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6011-6011

10.1200/jco.2015.33.15_suppl.6011 Get It

Genomic testing may offer therapeutic opportunity in salivary gland cancers.
Okuno, Scott H. , Price, Katharine A. , Chintakuntlawar, Ashish V.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e17053-e17053

10.1200/jco.2015.33.15_suppl.e17053 Get It

The use of patient-derived xenograft models for prioritizing therapeutic targets.
Topp, Monique, Hadley, Alison , Heong, Valerie , Harrell, Maria I., McNally, Orla , Lodhia, Kunal A., Study, Australian Ovarian Cancer, Scott, Clare L. , Hadley, Alison Maree, Fox, Stephen B. , Haluska, Paul , Bowtell, David D.L. , Swisher, Elizabeth M. , Wakefield, Matthew J. , Study, Australian Ovarian Cancer

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 5579-5579

10.1200/jco.2015.33.15_suppl.5579 Get It

The role of highly selective androgen receptor (AR) targeted therapy in men with biochemically relapsed hormone sensitive prostate cancer.
Aggarwal, Rahul , Alumkal, Joshi J. , Higano, Celestia S. , Yu, Margaret K. , Boer, Carla de, Choque-Gonzales, Gonzalo, Szmulewitz, Russell Z , Bryce, Alan H. , Small, Eric J.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS5084-TPS5084

10.1200/jco.2015.33.15_suppl.tps5084 Get It

Recalibration of genomic risk prediction models in prostate cancer to improve individual-level predictions.
Choeurng, Voleak, Luo, Bin , Yousefi, Kasra, Shin, Heesun , Haddad, Zaid , Ross, Ashley E. , Dicker, Adam P. , Karnes, R. Jeffrey , Thompson, Darby J. S., Dicker, Adam P , Davicioni, Elai , Schaeffer, Edward M. , Den, Robert B.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e16122-e16122

10.1200/jco.2015.33.15_suppl.e16122 Get It

Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial.
Manola, Judith , Wood, Christopher G. , Jewett, Michael A.S. , Coomes, Bob, Kuzel, Timothy M. , Sexton, Wade J. , Wong, Yu‐Ning, Пили, Роберто , DiPaola, Robert S. , Group, ECOG/ ACRIN 2805 Authors, Haas, Naomi B , Flaherty, Keith T. , Uzzo, Robert G. , Atkins, Michael B. , Dutcher, Janice P. , Kane, Christopher J. , Matin, Surena F. , Choueiri, Toni K. , Puzanov, Igor , Kohli, Manish , Stadler, Walter M. , Group, ECOG/ ACRIN 2805 Authors

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4508-4508

10.1200/jco.2015.33.15_suppl.4508 Get It

Multicenter prospective phase II trial of bevacizumab (bev) for progressive pancreatic neuroendocrine tumor (PNET).
Hobday, Timothy J. , Yin, Jun , Pettinger, Adam, Reidy‐Lagunes, Diane , Chen, Helen X., Erlichman, Charles , Strosberg, Jonathan

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4096-4096

10.1200/jco.2015.33.15_suppl.4096 Get It

Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Becerra, Carlos, Stephenson, Joe , Jonker, Derek J. , Cohn, Allen Lee, Asmis, Timothy R., Conkling, Paul , Garbo, Lawrence, Lenz, Heinz‐Josef , Richards, Donald , Mikhail, Sameh , Goodwin, Rachel , Yoon, Harry H. , Hume, Stephanie , Hitron, Matthew, Li, Chiang, Bekaii‐Saab, Tanios , Spira, Alexander I.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4069-4069

10.1200/jco.2015.33.15_suppl.4069 Get It

Comparison of HER2 gene amplification (AMP) in primary esophageal and gastroesophageal junction adenocarcinomas (EAC) and their metastatic regional lymph nodes (MLNs).
Yoon, Harry H. , Sukov, William R. , Sattler, Christopher A., Wiktor, Anne E., Diasio, Robert B. , Wu, Tsung‐Teh, Jenkins, Robert B. , Shi, Qian , Sinicrope, Frank A.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4059-4059

10.1200/jco.2015.33.15_suppl.4059 Get It